Abdul Rafeh Naqash

20PUBLICATIONS
158CO-AUTHORS
Animal systematics and taxonomyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Apr 18, 2026
Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.

|Dec 19, 2025
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer.

Amin H Nassar, Elias Bou Farhat, Hassan Abushukair

|Oct 07, 2025
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial.

Alison M Schram, Abdul Rafeh Naqash, Eric B Haura

|Jul 16, 2025
Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors.

Geraldine O'Sullivan Coyne, Khanh T Do, Shivaani Kummar

|Nov 22, 2024
Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis.

Jonathan N Priantti, Yu Fujiwara, Francisco Cezar Aquino de Moraes

|Feb 08, 2024
Association of Baseline Tumor-Specific Neoantigens and CD8+ T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors.

Csaba Kerepesi, Hassan Mohammed Abushukair, Biagio Ricciuti

Pageof 4

Frequent Collaborators

6 joint publications

Elad Sharon

5 joint publications

Amin H Nassar

3 joint publications

Naoko Takebe

3 joint publications

Geraldine O'Sullivan Coyne